HOME



Digby's Hullabaloo
2801 Ocean Park Blvd.
Box 157
Santa Monica, Ca 90405



Facebook: Digby Parton

Twitter:
@digby56
@Gaius_Publius
@BloggersRUs (Tom Sullivan)
@spockosbrain



emails:
Digby:
thedigbyblog at gmail
Dennis:
satniteflix at gmail
Gaius:
publius.gaius at gmail
Tom:
tpostsully at gmail
Spocko:
Spockosbrain at gmail
tristero:
Richardein at me.com








Infomania

Salon
Buzzflash
Mother Jones
Raw Story
Huffington Post
Slate
Crooks and Liars
American Prospect
New Republic


Denofcinema.com: Saturday Night at the Movies by Dennis Hartley review archive

January 2003 February 2003 March 2003 April 2003 May 2003 June 2003 July 2003 August 2003 September 2003 October 2003 November 2003 December 2003 January 2004 February 2004 March 2004 April 2004 May 2004 June 2004 July 2004 August 2004 September 2004 October 2004 November 2004 December 2004 January 2005 February 2005 March 2005 April 2005 May 2005 June 2005 July 2005 August 2005 September 2005 October 2005 November 2005 December 2005 January 2006 February 2006 March 2006 April 2006 May 2006 June 2006 July 2006 August 2006 September 2006 October 2006 November 2006 December 2006 January 2007 February 2007 March 2007 April 2007 May 2007 June 2007 July 2007 August 2007 September 2007 October 2007 November 2007 December 2007 January 2008 February 2008 March 2008 April 2008 May 2008 June 2008 July 2008 August 2008 September 2008 October 2008 November 2008 December 2008 January 2009 February 2009 March 2009 April 2009 May 2009 June 2009 July 2009 August 2009 September 2009 October 2009 November 2009 December 2009 January 2010 February 2010 March 2010 April 2010 May 2010 June 2010 July 2010 August 2010 September 2010 October 2010 November 2010 December 2010 January 2011 February 2011 March 2011 April 2011 May 2011 June 2011 July 2011 August 2011 September 2011 October 2011 November 2011 December 2011 January 2012 February 2012 March 2012 April 2012 May 2012 June 2012 July 2012 August 2012 September 2012 October 2012 November 2012 December 2012 January 2013 February 2013 March 2013 April 2013 May 2013 June 2013 July 2013 August 2013 September 2013 October 2013 November 2013 December 2013 January 2014 February 2014 March 2014 April 2014 May 2014 June 2014 July 2014 August 2014 September 2014 October 2014 November 2014 December 2014 January 2015 February 2015 March 2015 April 2015 May 2015 June 2015 July 2015 August 2015 September 2015 October 2015 November 2015 December 2015 January 2016 February 2016 March 2016 April 2016 May 2016 June 2016 July 2016 August 2016 September 2016 October 2016 November 2016 December 2016 January 2017 February 2017 March 2017 April 2017 May 2017 June 2017 July 2017 August 2017 September 2017 October 2017 November 2017 December 2017 January 2018 February 2018


 

This page is powered by Blogger. Isn't yours?

Hullabaloo


Wednesday, August 31, 2016

 
Mylan didn't lower EpiPen Prices — they just appeared to

by Gaius Publius


These days have seen a number of stories about the Mylan EpiPen scandal, the essence of which is captured in the graphic at the top (note, though, that the graphic understates the EpiPen price; it's now around $640). Heather Bresch, Mylan's CEO, decided to increase corporate profit by increasing the price of a mature product, EpiPen, a device that delivers life-saving epinephrine to people who suffer life-threatening anaphylactic shock from allergic exposure to, for example, bee stings and peanuts.

In the view of most observers, she did it simply because she could.


West Virginia Democratic Senator Joe Manchin's daughter Heather Bresch, CEO of Mylan, and some of the work she's been doing. Note — the EpiPen price is actually around $640 at most pharmacies (source).


There's no economic reason for the price increases, any of them. Epinephrine (basically adrenalin) is not proprietary. As Dr. Lee Rogers notes in the first link below, "As a hormone, it's a product of nature and cannot be patented." And the delivery mechanism (the "pen") has been around since 1977. All of the R&D is done, and the medicine is cheap. All told, each EpiPen contains just one dollar worth of medicine. (And it seems the original EpiPen was at least partly developed with taxpayer money.)

Yet under Heather Bresch, Mylan has steadily raised the price from about $50, its price when Mylan acquired the 50-year-old product, to more than $600 — because they could. In 2009, the year Bresch became president, the price of the EpiPen was increased 19%, followed by 10% hikes each year from 2010 through 2013. Then:
After successfully pushing for legislation requiring all public schools to carry emergency epinephrine [devices], Mylan jacked up the price by 15 percent every other quarter from the end of 2013 to the second quarter of 2016 [emphasis mine].
And that's how the game is played.

A shakedown scheme with a sidecar of murder

As I noted here, this is basically a shakedown scheme with a sidecar of murder — "Got a peanut allergy? Pay my new price or the kid dies." In the meantime, corporate profit went through the roof, as did CEO compensation, as the graphic shows.

Dr. Lee Rogers, a medical doctor and former progressive House candidate, broke the story at DownWithTyranny:


There's a good follow-up here:


Two side wrinkles and you're up to date:

First, CEO Bresch may have engaged in insider trading when she sold over 100,000 shares of Mylan stock in advance of the latest price increases. As noted in the second link above, the stock price fell drastically after Dr. Rogers' piece was published.

Second, Bresch has taken Mylan through a corporate "inversion," a scheme by which a U.S. company buys a foreign subsidiary, then becomes a foreign corporation, with nothing else changing but its U.S. tax status. LA Times reporter Michael Hiltzik has written a full report on Mylan's inversion here.

Shamed by the scandal, Heather Bresch pretended to lower EpiPen's price

Mylan's price-gouging on its EpiPen business is indeed a scandal, not just on the business pages because of the sudden stock decline, but in the larger press because of the "vulture CEO" angle. Even MSNBC, which tends to keep hands off of Democrats, covered it, and tagged Sen. Joe Manchin in the story. (For more on Manchin and his responsibility for his daughter's career, do read Dr. Rogers' well researched story. Manchin's been involved at almost every stage of it.)

As a result of the horrible press, Mylan responded. It was initially reported that Mylan would lower the price of its EpiPen package by 50% in response to public outrage. For example, from The Hill:
EpiPen maker lowers price after uproar

The maker of EpiPens announced Thursday that it is reducing the price of the device following an uproar in Washington over the cost of the treatment for serious allergic reactions.

Mylan, the company that makes EpiPen, said it will provide a savings card worth up to $300 for people who had been paying the full price out-of-pocket, effectively reducing the cost by 50 percent.

The company is also making it easier to qualify for its patient assistance program, which eliminates out-of-pocket costs for uninsured and underinsured people....

Mylan announced the changed a day after Hillary Clinton denounced the company for hiking the cost of EpiPens 400 percent in recent years. Lawmakers on Capitol Hill had also sounded the alarm, sending letters to the company and to the Food and Drug Administration pressing for answers.

Mylan also pointed to insurance companies in its Thursday statement, noting that higher deductibles have left patients picking up more of the cost of drugs like EpiPens.
I hope you noted that last sentence, in which Mylan says "higher deductibles have left patients picking up more of the cost of drugs like EpiPens." Remember, each EpiPen contains about $1 worth of medicine. Patients are actually picking up the cost of CEO Bresch's nearly 700% compensation increase.

But it didn't take long for that "50% reduction in cost" claim to be more carefully looked at. For example, from USuncut:
EpiPen did not actually lower their price — it’s just another Pharma scam

Mylan Pharmaceuticals is now running a slick PR campaign to try and convince Americans they lowered the price of the EpiPen. Don’t buy it.

On Thursday morning, it was widely reported that Mylan responded to consumer outrage by lowering the price of the drug by 50 percent. While that may be true on the surface, the company didn’t actually change the price at all. The drug company’s rollout of EpiPen price cuts only applies to uninsured and underinsured consumers, who are given a $300 savings card while still having to pay roughly $300 more for a [$640] package of two EpiPens.
The bottom line?
However, the market price of the EpiPen remains the same.
And that's how the game is played.

This is Heather Manchin Bresch, by the way, in case you see her on the street. I'm sure she'd be glad to explain the numerous price increases at length. Maybe there's a nuance she can point you to that I've missed.


Mylan CEO Heather Bresch (source; photo credit Joe Wojcik)


Or maybe not. This really is shakedown scheme, with a sidecar of "or your kid dies." Is predator too strong a word for this behavior? Or is predation just business as usual in drug company CEO suites and the DC political offices that take their money?

Hate the drug companies? Support California's Prop 61 in November

If you think predator is not too strong a word for drug company "shakedown or death" profit schemes, consider supporting California's new Proposition 61, which will end Big Pharma's hold on unchecked and sky-high prices. Prop 61 is a serious attack on drug pricing, and it will work if it's passed. It will also appear in a number of other states if it's passed — hope for us all.

More on Prop 61 here.

(A version of this piece appeared at Down With Tyranny. GP article archive here.)

GP
 

.